Both Skyrizi and Ilumya are IL-23 monoclonal antibodies that may be given for the treatment of moderate to severe plaque psoriasis. There are several differences between them:

• Ilumya was FDA approved in 2018 and Skyrizi was FDA approved in 2019
• Ilyumya is a brand name for tildrakizumab and Skyrizi is a brand name for risankizumab
• The dose of Skyrizi is 150mg, but because each injection only contains 75mg, two injections must be given per dose. The dose of Ilumya is 100mg, and each injection contains 100mg therefore only one injection needs to be given each time
• Ilumya needs to be administered by a health care professional; however, patients prescribed Skyrizi can be taught how to self-administer it at home
• Skyrizi is also approved to treat adults with active psoriatic arthritis (PsA) and Crohn's disease.

Comparative trials comparing Skyrizi to Ilumya are lacking; however, a trial that compared Skyrizi to Stelara showed that it has a fast onset of action with 44% of participants achieving PASI 90 by week four compared with only 19% of those administered Stelara.

There are several similarities between Skyrizi and Ilumya:

• Both are approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
• Both Skyrizi and Ilumya are dosed every 12 weeks after an initial loading dose period
• Either may be given as monotherapy or in addition to other therapies
• Side effects are similar.